A review on the classification and current treatment of Chronic Kidney Disease
DOI:
https://doi.org/10.12775/JEHS.2023.49.01.006Keywords
Chronic Kidney Disease, Kidney Failure, Chronic TreatmentAbstract
Introduction:
Chronic Kidney Disease (CKD) is a chronic condition which is characterized by the gradual loss of kidney function over time leading to End-Stage Renal Disease (ESRD). Role of kidneys is very vital to maintain homeostasis of the system. CKD is classified into five stages based on the estimated Glomerular Filtration Rate (eGFR). CKD is a long-term condition which cannot be completely cured. Treatment focuses on managing underlying conditions , slowing disease progression and addressing complications.
Aim of the study:
Purpose of this study is to encapsulate available knowledge about classification and therapeutic options for patients with Chronic Kidney Disease and End-Stage Kidney Disease. Both old and new treatment methods have been summarized in the following publication.
Material and methods:
Literature available in the PubMed database was reviewed using the following keywords:
“Chronic kidney disease”, “ACE inhibitors” , “Angiotensin II Type 1 Receptor Blockers", “Diabetic Kidney Disease” ,”End-Stage Kidney Disease”, “Dapagliflozin”,
Conclusions:
Chronic Kidney Disease is a condition which is progressive and affects more than 10% of the general population worldwide totaling over 800 million people. There are many causes of chronic kidney disease; therefore, it is important to focus on slowing the progression of the disease, minimizing complications and modifying risk factors.
References
Davidson. Choroby wewnętrzne. Tom 1. Red. Stuart H. Ralson, Ian D. Penman, Mark W. J. Strachan, Richard P. Hobson. Edra Urban & Partner. Wydanie 2 polskie 2020.
Interna Szczeklika 2022. Podręcznik chorób wewnętrznych. Red. Piotr Gajewski, Andrzej Szczeklik. Medycyna Praktyczna. Wydanie 13. 2022.
Thurlow JS, Joshi M, Yan G, Norris KC, Agodoa LY, Yuan CM, Nee R. Global Epidemiology of End-Stage Kidney Disease and Disparities in Kidney Replacement Therapy. Am J Nephrol. 2021;52(2):98-107. doi: 10.1159/000514550. Epub 2021 Mar 22. PMID: 33752206; PMCID: PMC8057343.
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022 Apr;12(1):7-11. doi: 10.1016/j.kisu.2021.11.003. Epub 2022 Mar 18. PMID: 35529086; PMCID: PMC9073222.
Jager K.J., Kovesdy C., Langham R., et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96:1048–1050.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013; 3:1-150
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-266. [PMID: 11904577]
Gusev E, Solomatina L, Zhuravleva Y, Sarapultsev A. The Pathogenesis of End-Stage Renal Disease from the Standpoint of the Theory of General Pathological Processes of Inflammation. Int J Mol Sci. 2021 Oct 23;22(21):11453. doi: 10.3390/ijms222111453. PMID: 34768884; PMCID: PMC8584056.
Drawz P, Rahman M. Chronic kidney disease. Ann Intern Med. 2015 Jun 2;162(11):ITC1-16. doi: 10.7326/AITC201506020. PMID: 26030647.
Jin R, Grunkemeier GL, Brown JR, Furnary AP. Estimated glomerular filtration rate and renal function. Ann Thorac Surg. 2008 Jul;86(1):1-3. doi: 10.1016/j.athoracsur.2008.05.007. PMID: 18573388.
Inker LA, Titan S. Measurement and Estimation of GFR for Use in Clinical Practice: Core Curriculum 2021. Am J Kidney Dis. 2021 Nov;78(5):736-749. doi: 10.1053/j.ajkd.2021.04.016. Epub 2021 Sep 11. PMID: 34518032.
Usherwood T, Lee V. Advances in chronic kidney disease pathophysiology and management. Aust J Gen Pract. 2021 Apr;50(4):188-192. doi: 10.31128/AJGP-11-20-5735. PMID: 33786542.
Ameer OZ. Hypertension in chronic kidney disease: What lies behind the scene. Front Pharmacol. 2022 Oct 11;13:949260. doi: 10.3389/fphar.2022.949260. PMID: 36304157; PMCID: PMC9592701.
Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045. doi: 10.2215/CJN.11491116. Epub 2017 May 18. PMID: 28522654; PMCID: PMC5718284.
Xia J, Wang L, Ma Z, Zhong L, Wang Y, Gao Y, He L, Su X. Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Nephrol Dial Transplant. 2017 Mar 1;32(3):475-487. doi: 10.1093/ndt/gfw452. PMID: 28339863.
Gilligan S, Raphael KL. Hyperkalemia and Hypokalemia in CKD: Prevalence, Risk Factors, and Clinical Outcomes. Adv Chronic Kidney Dis. 2017 Sep;24(5):315-318. doi: 10.1053/j.ackd.2017.06.004. PMID: 29031358.
Madero M, García-Arroyo FE, Sánchez-Lozada LG. Pathophysiologic insight into MesoAmerican nephropathy. Curr Opin Nephrol Hypertens. 2017 Jul;26(4):296-302. doi: 10.1097/MNH.0000000000000331. PMID: 28426518.
Khan SR, Pearle MS, Robertson WG, Gambaro G, Canales BK, Doizi S, Traxer O, Tiselius HG. Kidney stones. Nat Rev Dis Primers. 2016 Feb 25;2:16008. doi: 10.1038/nrdp.2016.8. PMID: 27188687; PMCID: PMC5685519.
Peralta, Carmen A., et al. "Association of antihypertensive therapy and diastolic hypotension in chronic kidney disease." Hypertension 50.3 (2007): 474-480.
Xiaojing Wu, Wen Zhang, Hong Ren, Xiaonong Chen, Jingyuan Xie & Nan Chen (2014) Diuretics associated acute kidney injury: clinical and pathological analysis, Renal Failure, 36:7, 1051-1055, DOI: 10.3109/0886022X.2014.917560
Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018 Dec;14(12):727-749. doi: 10.1038/s41581-018-0072-9. Erratum in: Nat Rev Nephrol. 2019 Feb;15(2):121. PMID: 30361677.
Vaidya SR, Aeddula NR. Chronic Kidney Disease. 2022 Oct 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 30571025.
Textor SC. Ischemic nephropathy: where are we now? J Am Soc Nephrol. 2004 Aug;15(8):1974-82. doi: 10.1097/01.ASN.0000133699.97353.24. PMID: 15284283.
Barutta F, Bellini S, Gruden G. Mechanisms of podocyte injury and implications for diabetic nephropathy. Clin Sci (Lond). 2022 Apr 14;136(7):493-520. doi: 10.1042/CS20210625. PMID: 35415751; PMCID: PMC9008595.
Torra R. Autosomal dominant policystic kidney disease, more than a renal disease. Minerva Endocrinol. 2014 Jun;39(2):79-87. PMID: 24736482.
Rajasekaran A, Julian BA, Rizk DV. IgA Nephropathy: An Interesting Autoimmune Kidney Disease. Am J Med Sci. 2021 Feb;361(2):176-194. doi: 10.1016/j.amjms.2020.10.003. Epub 2020 Oct 8. PMID: 33309134; PMCID: PMC8577278.
Klahr S. Obstructive nephropathy. Intern Med. 2000 May;39(5):355-61. doi: 10.2169/internalmedicine.39.355. PMID: 10830173.
Ammirati AL. Chronic Kidney Disease. Rev Assoc Med Bras (1992). 2020 Jan 13;66Suppl 1(Suppl 1):s03-s09. doi: 10.1590/1806-9282.66.S1.3. PMID: 31939529.
Moyer VA; U.S. Preventive Services Task Force. Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012 Oct 16;157(8):567-70. doi: 10.7326/0003-4819-157-8-201210160-00533. PMID: 22928170.
Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019 Oct 1;322(13):1294-1304. doi: 10.1001/jama.2019.14745. PMID: 31573641; PMCID: PMC7015670.
Piperidou A, Loutradis C, Sarafidis P. SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. J Hum Hypertens. 2021 Jan;35(1):12-25. doi: 10.1038/s41371-020-00393-4. Epub 2020 Aug 10. PMID: 32778748.
Baker, L.A., March, D.S., Wilkinson, T.J. et al. Clinical practice guideline exercise and lifestyle in chronic kidney disease. BMC Nephrol 23, 75 (2022). https://doi.org/10.1186/s12882-021-02618-1
Locatelli F, Nissenson AR, Barrett BJ, Walker RG, Wheeler DC, Eckardt KU, Lameire NH, Eknoyan G. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2008 Nov;74(10):1237-40. doi: 10.1038/ki.2008.299. Epub 2008 Jul 2. PMID: 18596731.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017 Jul;7(1):1-59. doi: 10.1016/j.kisu.2017.04.001. Epub 2017 Jun 21. Erratum in: Kidney Int Suppl (2011). 2017 Dec;7(3):e1. PMID: 30675420; PMCID: PMC6340919.
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020 Jun;75(6):1334-1357. doi: 10.1161/HYPERTENSIONAHA.120.15026. Epub 2020 May 6. PMID: 32370572.
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022 Nov;102(5S):S1-S127. doi: 10.1016/j.kint.2022.06.008. PMID: 36272764.
Guidelines for vaccination in patients with chronic kidney disease. Indian J Nephrol. 2016 Apr;26(Suppl 1):S15–8. PMCID: PMC4928524.
Banach M, Burchardt P, Chlebus K, et al. WYTYCZNE PTL/KLRwP/PTK/
PTDL/PTD/PTNT DIAGNOSTYKI I LECZENIA ZABURZEŃ LIPIDOWYCH W POLSCE 2021. Lekarz POZ Suplement. 2021.
Wanner C, Tonelli M; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014 Jun;85(6):1303-9. doi: 10.1038/ki.2014.31. Epub 2014 Feb 19. PMID: 24552851.
Beimler J. Neue Aspekte der medikamentösen Nephroprotektion [New aspects of pharmacological nephroprotection]. Inn Med (Heidelb). 2022 Nov;63(11):1200-1207. German. doi: 10.1007/s00108-022-01297-w. Epub 2022 Apr 5. Erratum in: Inn Med (Heidelb). 2022 Oct 20;: Erratum in: Inn Med (Heidelb). 2023 Feb;64(2):204. PMID: 35380212.
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021 Mar;99(3S):S1-S87. doi: 10.1016/j.kint.2020.11.003. PMID: 33637192.
Fioretto P, Avogaro A. Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opin Pharmacother. 2017 Apr;18(5):517-527. doi: 10.1080/14656566.2017.1300253. Epub 2017 Mar 20. PMID: 28277831.
Raport o stanie leczenia nerkozastępczego Polska 2021. Alicja Dębska-Ślizień, Bolesław Rutkowski, Piotr Jagodziński i in.
Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, Zhao MH, Lv J, Garg AX, Knight J, Rodgers A, Gallagher M, Kotwal S, Cass A, Perkovic V. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015 May 16;385(9981):1975-82. doi: 10.1016/S0140-6736(14)61601-9. Epub 2015 Mar 13. PMID: 25777665.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021. PMID: 34556256.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Michał Żuberek, Zuzanna Popińska, Daniel Ślusarczyk, Bartłomiej Żmuda, Wiktoria Jakubowska, Piotr Pisera, Aleksandra Kiełkowicz, Filip Pactwa
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 281
Number of citations: 0